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Calcitonin gene-related peptide (CGRP) is a potent
vasodilator and sensory neuropeptide implicated in the
pathophysiology of migraine headache. CGRP receptor
(CGRP-R) antagonists, including telcagepant, have
shown clinical efficacy in treating migraine. CGRP-Rs
are expressed in the CNS, particularly in the brainstem
and cerebellum as well as in the periphery on vascular
smooth muscle cells. To investigate whether central
CGRP-Rs were likely to be involved in the anti-migraine
effects of CGRP-R antagonists we examined central
CGRP-R occupancy (CGRP RO) at an efficacious dose
of telcagepant in healthy volunteers and in migraineurs
during ictal and interictal periods using the novel PET
tracer [11C]MK-4232. CGRP RO was evaluated in
healthy subjects (n=3) at the lowest clinically efficacious
dose (140 mg, PO) of telcagepant ~2h after dosing,
coinciding with the time point of efficacy evaluation in
clinical migraine studies. PET imaging showed only low
CGRP RO (4% - 10%) which is within test-retest varia-
bility, suggesting that central activity is not a pre-requi-
site for anti-migraine efficacy of CGRP-R antagonists. A
supratherapeutic telcagepant dose (1120 mg, PO) pro-
duced only moderate (43-58%, n=4) CGRP RO at
~Tmax (3h after administration). Subsequently, the pos-
sibility that brain penetration of telcagepant, a P-gp
brain efflux pump substrate, may be increased in
migraine patients or during migraine by blood brain
barrier opening, was investigated by PET studies in the
ictal and interictal periods in migraineurs (n=3) ~2 h
after telcagepant dosing (140 mg, PO). Comparison of
[11C]MK-4232 PET study results from ictal and interic-
tal periods in migraineurs to healthy volunteers, suggests
similar low RO and no significant differences between
states. In conclusion, PET studies with the CGRP-R
PET tracer [11C]MK-4232 after therapeutic doses of tel-
cagepant in healthy volunteers and migraineurs suggest
that central antagonism of CGRP-R is not necessary for
therapeutic efficacy in migraine pain relief and that
migraine pain is therefore at least in part peripheral in
origin.
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